-
Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case.
Chiecchio L, Dagrada GP, Protheroe RK, Stockley DM, Smith AG, Orchard KH, Cross NC, Harrison CJ, Ross FM, UK Myeloma Forum.
Haematologica. 2009 Jul; 94(7):1024-8. Epub 2009 May 19.
[Haematologica. 2009]
-
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S, Pineda-Roman M, Hollmig K, Alsayed Y, Hoering A, Szymonifka J, et al.
Blood. 2008 Oct 15; 112(8):3122-5. Epub 2008 Jul 31.
[Blood. 2008]
-
Review of thalidomide in the treatment of newly diagnosed multiple myeloma.
Cavallo F, Boccadoro M, Palumbo A.
Ther Clin Risk Manag. 2007 Aug; 3(4):543-552.
[Ther Clin Risk Manag. 2007]
- » See all...